Multicenter phase II study of FOLFIRI plus bevacizumab after discontinuation of oxaliplatin-based regimen for advanced or recurrent colorectal cancer (CR0802)

BACKGROUND: To investigate the efficacy and safety of FOLFIRI plus bevacizumab regimen with irinotecan (180 mg/m(2)) in patients with advanced or recurrent colorectal cancer who were of the wild-type or heterozygous group for UGT1A1*28 and *6 polymorphisms and discontinued to oxaliplatin-based regim...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:BMC Cancer
Main Authors: Suenaga, Mitsukuni, Nishina, Tomohiro, Mizunuma, Nobuyuki, Yasui, Hisateru, Ura, Takashi, Denda, Tadamichi, Ikeda, Junichi, Esaki, Taito, Nishisaki, Hogara, Takano, Yoshinao, Sugiyama, Yasuyuki, Muro, Kei
פורמט: Artigo
שפה:Inglês
יצא לאור: BioMed Central 2015
נושאים:
Research Article
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC4376520/
https://ncbi.nlm.nih.gov/pubmed/25884814
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-015-1175-3
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים